BALFAXAR: payments to doctors
Payments that named BALFAXAR as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $107K
- Providers
- 465
- Transactions
- 660
- Average per transaction
- $162
The per-transaction average — $162 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 465 providers the average total is $230, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Octapharma USA, Inc. | $106,876 | 100.0% |